Repurposing manufacturing lines for providing medical and other products and ser...
Repurposing manufacturing lines for providing medical and other products and services in case of spiking demand times
RESERVIST aims to establish ‘reservist cells’ that in times of crises can be activated within 48hrs to switch to manufacturing medical products and services that are spiking in demand. Such a ‘reservist cell’ will consist of (i) a...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto RESERVIST
Duración del proyecto: 31 meses
Fecha Inicio: 2020-10-30
Fecha Fin: 2023-05-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
RESERVIST aims to establish ‘reservist cells’ that in times of crises can be activated within 48hrs to switch to manufacturing medical products and services that are spiking in demand. Such a ‘reservist cell’ will consist of (i) a backbone network of core companies for manufacturing and testing; (ii) an extended network for further capacities (eg local provision, packaging, distribution, customization,…); (iii) a digital coordination platform and (iv) a pool of experts from the companies of the network. These cells will become operational in case of an emergency/pandemic but to make economic sense, the same approach of rapid flexibility and adaptability will be used to deal with surging demand in ‘normal circumstances’.
To realise this concept, we will first work on three levels individually: network level, connected manufacturing/digital manufacturing level and technical level, the latter referring to tweaking manufacturing lines, developing required materials and establishing links with testing/certification. Next, we will demonstrate the repurposing of 5 existing manufacturing lines within 48hrs towards manufacturing of ‘textile PPE’ (surgical and respiratory face masks, medical aprons) and ‘respiratory ventilators’ (invasive and non invasive) that comply with necessary testing and certification and proceed with the embedment of the reservist cells at the partners in the network. We will develop blueprints for further take-up and replication of the concept to other sectors. Within the project we will develop two replication demos: ‘disinfection equipment’ and ‘emergency medical equipement’. To support the Cells we will tap into the worldwide maker community and into relevant OITBs and networks.
The consortium is strongly industry-driven, including 4 LE and 7 SMEs coming from 7 EU countries. To maximise impact, we will extend our partner network and our Impact Support Group (18 Support Letters provided at proposal stage).